- info@bpc157.si
ABOUT US
Company Diagen d.o.o. was founded in 1993 by scientists and physicians to become company dedicated to technological advancements in the Research & Development of new medicines origin from Humans. In Humans we have discovered and isolated human gastric juice Body Protecting Compound Protein (BPC) which helps and initiates the body activate its innate healing processes.
Based on our Research & Development we were able to determine amino acid sequence of human Body Protecting Compound Protein (BPC), responsible for its activity and therefore develop BPC 157, which is 15 amino acids fragment responsible for the biological activity of human BPC.
We are the originator of human Body Protecting Compound Protein (BPC), BPC 157 as well as a Patent owner of special stable version of BPC 157 (BPC 157 Stable) which has much higher stability than any other version. Since our Patented Stable version of BPC 157 showed superiority to any other BPC 157 we use for all our animal studies only BPC 157 Stable form.
Our CEO is Prof. Predrag Sikirić, MD, PhD who is also a professor in the department of Pharmacology in University of Zagreb, Croatia. He is specialized in Cardiovascular Sciences, Musculoskeletal Sciences, Neuroscience, and Resuscitation Sciences. He is a leading European scientist in Diagen and has discovered Human Body Protecting Compound (BPC) from Human Gastric Juice. Together with company Diagen’s team we have further developed BPC into BPC 157 and its latest Patented version Stable BPC 157. With several animal studies performed, Prof. Sikirić together with his team and Diagen confirmed beneficial biological activities of BPC and Stable BPC 157 for prevention, prophylaxis and treatment of the following diseases and disease conditions:
Gastrointestinal tract related disease
Chron’s disease, ulcers in any part of the gastrointestinal tract, general anti-inflammatory activity, gastrointestinal inflammatory disease, acute pancreatitis
Organ protective activity
Organ protective activity: protection of hepatic and pancreatic lesions, protection of endothelial cells, prevention of adhesion formation, prevention and treatment of myocardial infarction and brain stroke, protective effect in immune system
Treatment of viral infections
Treatment of viral infections, particularly with West Nile, Dengue types 1-4, hepatitis A virus, herpes strain influenza A virus and ARBO viruses, such as tick borne encephalitis, cytomegalovirus CMV and LCM virus, feline leukemia virus
Accelerated healing of Burns
Accelerated healing of burns
Accelerated healing of wounds and nerve linkages
Accelerated healing of wounds, muscle, tendon, ligament, regeneration of ruptured nerve linkages
Healing Achilles' tendon
Accelerated healing of Achilles’ tendon and bone fractures
Healing of spinal cord injury
Healing of spinal cord injury
Treatment of hypertension
Treatment of organic disorders associated with NO formation: hypertension, hypotension, anaphylaxis, circulatory and septic shock, aggregation of thrombocytes
Treatment of neurological diseases and disorders; Multiple sclerosis, Parkinson disease model, encephalopathies etc.
Treatment of neurological diseases and disorders: Multiple sclerosis, myasthenia gravis, lupus erythematosus, neuropathy, dysfunction of somatosensory nerves, asthma, rhinitis, pemphigus and eczema
Reorganization of rapid blood recirculation
Therapy in all conditions, in which rapid reorganization of blood circulation is mandatory
Healing eye diseases
Treatment of Glaucoma, Retinal Ischemia, Corneal ulcer therapy
Unleashing the Power of Innovation in New Drug Development
Prof. Predrag Sikirić, PhD
Prof. Predrag Sikirić is a leading scientist in Cardiovascular Sciences,
Musculoskeletal Sciences, Neuroscience, Resuscitation Sciences.
WHO ARE WE?
- Collaborative Approach
- Rigorous Quality Control
- Ethical and Sustainable Practices
- Cutting-Edge Research
- Technological Expertise
- Focus on Patient Outcomes